PSA velocity and PSA slope

Prostate Cancer and Prostatic Diseases

Volumn 9, Issue 2, 2006, Pages 169-172

  Benecchi, Luigi ^a,b  

^a Fidenza Hospital   (Italy)

^b NONE   (Italy)

Author keywords

Prostate specific antigen; PSA slope; PSA velocity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ANTIGEN DETECTION; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PLOTS AND CURVES; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; TRANSRECTAL ULTRASONOGRAPHY; VELOCITY;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CASE-CONTROL STUDIES; COHORT STUDIES; ENDOSONOGRAPHY; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 33745654719     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500866     Document Type: Article

References (23)

1. Kirbly SR, Christmas TJ, Brawer MK. Prostate Cancer (2nd edition). Mosby (London, England), 2001, 59-71.
2. Young J (Ed). Cancer Incidence in Five Continents. Lyon, France, International Agency for Research on Cancer, vol VII 1997.
3. Catalona WJ, Smith DS, Ratliff TL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-1161.
4. Woolf SH. Screening for prostate cancer with prostate-specific antigen. An examination of evidence. N Engl J Med 1995; 1333: 1401-1405.
5. Karazanashvili G, Abrahamsson PA. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. J Urol 2003; 169: 445-457.
6. Benecchi L, Pieri AM. Utilizzo pratico di una semplice rete neurale nella diagnosi dell'adenocarcinoma prostatico. Urologia 2005; 72: 78-84.
7. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-2220.
8. Roobol MJ, Kranse R, De Koning HJ, Schroder FH. Prostate-specific antigen velocity at low prostate-specific antigens levels as screening tool for prostate cancer: Results of second screening round of ERSPC (Rotterdam). Urology 2004; 63: 309-315.
9. D'Amico AV, Ming-Hui C, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from postate cancer after radical prostatectomy. N Eng J Med 2004; 351: 125-135.
10. Khan MA, Carter HB, Epstein JI, Miller MC, Landis P, Walsh PW et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 2003; 170: 2274-2278.
11. Carter HB, Pearson JD, Waclawiw Z, Metter EJ, Chan DW, Guess HA et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 1995; 45: 591-596.
12. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839.
13. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29.
14. Catalona WL, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-954.
15. Catalona WJ, Richie P, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283-1290.
16. Reissigl A, Klocker H, Pointner J, Fink K, Horninger W, Ennemoser O et al. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening. Urology 1996; 48: 62-66.
17. Carter H, Morrell CH, Pearson JD, Brant LJ, Plato CC, Metter EJ et al. Estimation of prostatic growth using serial PSA measurements in men with and without prostate disease. Cancer Res 1992; 52: 3323-3328.
18. Brawer M, Beatie J, Wener M, Vessella R, Preston S, Lange P. for prostatic carcinoma with PSA: Results of the second year. J Urol 1993; 150: 106-109.
19. Porter JR, Hayward R, Brawer MK. The significance of short term PSA change in men undergoing ultrasound guided prostate biopsy. J Urol 1994; 164: 293A.
20. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994; 152: 1168-1169.
21. Raaijmakers R, Wildhagen MF, Ito K, Paez A, De Vries SH, Roobol MJ et al. Prostate specific antigen in the European randomized study of screening for prostate cancer, Section Rotterdam. Urology 2004; 63: 316-320.
22. Takamiya R, Weinberg V, Young D, Sandler H, McLaughlin P, Roach M. A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2003; 56: 1073-1078.
23. Komatsu K, Wehner N, Prestigiacomo AF. Physiologic (intra-individual) variation of serum prostate-specific antigen in 814 men from a screening population. Urology 1996; 47: 343-346.